What are the therapeutic advantages of ceritinib (ceritinib)? Comparison with other drugs

Ceritinib (trade name: Zykadia, often called Ceritinib in Chinese) is a second-generation ALK (anaplastic lymphoma kinase) inhibitor, mainly used to treat patients with ALK-positive non-small cell lung cancer (NSCLC). Since it was approved by the US FDA for use in patients who are resistant or intolerant to crizotinib (Crizotinib), its application value and advantages in clinical treatment have gradually become prominent. Ceritinib has obvious clinical advantages in terms of target specificity, ability to penetrate the central nervous system, and response to drug-resistant mutations, and to a certain extent, it has filled the treatment gap of the first-generation ALK inhibitors.

First of all, compared with the first-generation ALK inhibitor crizotinib, ceritinib has obvious advantages in efficacy. Studies have shown that the affinity of ceritinib for the ALK target is more than 20 times that of crizotinib, which means that it can inhibit the ALK signaling pathway more effectively, thereby controlling the growth and spread of tumor cells. For those patients who develop resistance mutations during crizotinib treatment, such as L1196M, G1269A and other common ALK mutation sites, ceritinib still shows good inhibitory effects, making it an important treatment alternative after crizotinib resistance.

Secondly, ceritinib has excellent performance in penetrating the blood-brain barrier. Central nervous system (CNS) metastasis is a common and serious clinical problem in ALKpositiveNSCLC patients, and crizotinib has limited ability to control brain metastases due to poor blood-brain barrier permeability. In contrast, ceritinib has strong central penetration ability, and multiple clinical studies have confirmed that it can effectively reduce tumor burden and prolong progression-free survival (PFS) in patients with brain metastases. Therefore, ceritinib provides a more targeted treatment for patients who have developed or are at high risk of developing brain metastases.

Thirdly, ceritinib has also shown satisfactory results in multiple clinical trials in terms of duration of treatment response and progression-free survival. For example, in the ASCEND series of studies, the objective response rate (ORR) of ceritinib in crizotinib-resistant patients exceeded40%, the median progression-free survival is 6.9 months, and the PFS of some patients with brain metastases is even longer. For untreated ALK-positive advanced NSCLC patients, ceritinib is used as a first-line treatment option, PFScan reach 16.6 months, which is better than crizotinib’s 10.9 months.

Although ceritinib has many advantages in efficacy, its side effects cannot be ignored. The most common adverse reactions include nausea, diarrhea, vomiting, abnormal liver function, etc. Therefore, it is necessary to pay attention to dosage adjustment and side reaction monitoring in practical applications. It is worth mentioning that the tolerability of ceritinib has improved in recent years with the optimization of doses and improvements in postprandial administration strategies. For example, by lowering the dose to 450 mg and taking it with food, the efficacy can be maintained while reducing gastrointestinal side effects.

In general, ceritinib, as a second-generation ALK inhibitor, plays a key role in the treatment of crizotinib resistance. Its advantages include higher target affinity, greater central nervous system penetration, more durable therapeutic responses, and broad coverage of multiple ALK resistance mutations. Compared with other second- and third-generation ALK inhibitors that are subsequently marketed, such as alectinib (Alectinib), lorlatinib (Lorlatinib), ceritinib still has the advantages of cost-effectiveness and accessibility, especially in some areas with limited medical insurance or drug access. It is one of the important treatment options for patients with ALK-positive NSCLC. With the development of precision medicine, ceritinib may be used in combination with other targeted drugs, immunotherapy, etc. in the future to bring more benefits to lung cancer patients.

Reference materials:https://www.novartis.com/our-products/pipeline/ceritinib